Literature DB >> 12709437

Adaptor protein 3BP2 is a potential ligand of Src homology 2 and 3 domains of Lyn protein-tyrosine kinase.

Koichiro Maeno1, Kiyonao Sada, Shinkou Kyo, S M Shahjahan Miah, Keiko Kawauchi-Kamata, Xiujuan Qu, Yuhong Shi, Hirohei Yamamura.   

Abstract

Adaptor protein 3BP2, a c-Abl-Src homology 3 (SH3) domain-binding protein, is known to play a regulatory role in T-cell receptor-mediated transcriptional activation of nuclear factor of activated T cell and activator protein 1 by interacting with Syk/ZAP-70 protein-tyrosine kinase. We have previously demonstrated that aggregation of high affinity IgE receptor (FcepsilonRI) induces tyrosine phosphorylation of 3BP2, and overexpression of the 3BP2-SH2 domain suppresses antigen-induced degranulation in rat basophilic leukemia RBL-2H3 mast cell line. In this report, we attempt to analyze the biological relevance of 3BP2 tyrosine phosphorylation. By using the transient expression system in COS-7 cells, we have demonstrated that 3BP2 was predominantly phosphorylated on Tyr174, Tyr183, and Tyr446 when it was coexpressed with Syk. An in vitro binding study revealed that phosphorylation of Tyr446 by Syk was likely to create a binding site for the Lyn-SH2 domain in RBL-2H3 cells. In addition, proline-rich region of 3BP2 bound to the Lyn-SH3 domain. Conformational microscopic analysis showed that Lyn and 3BP2 are constitutively colocalized in RBL-2H3 cells. Overexpression of 3BP2 in RBL-2H3 cells resulted in an enhancement of Lyn autophosphorylation. These results suggest that the adaptor protein 3BP2 is a potential regulator of Lyn protein-tyrosine kinase as a ligand of its SH3/SH2 domains in FcepsilonRI-mediated signaling in mast cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12709437     DOI: 10.1074/jbc.M301201200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  3BP2 deficiency impairs the response of B cells, but not T cells, to antigen receptor ligation.

Authors:  Miguel A de la Fuente; Lalit Kumar; Bao Lu; Raif S Geha
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

2.  Decreased SH3BP2 inhibits osteoclast differentiation and function.

Authors:  Teruya Kawamoto; Chun Fan; Robert J Gaivin; Michael A Levine; Steven A Lietman
Journal:  J Orthop Res       Date:  2011-03-29       Impact factor: 3.494

3.  Alveolar Bone Protection by Targeting the SH3BP2-SYK Axis in Osteoclasts.

Authors:  Mizuho Kittaka; Tetsuya Yoshimoto; Collin Schlosser; Robert Rottapel; Mikihito Kajiya; Hidemi Kurihara; Ernst J Reichenberger; Yasuyoshi Ueki
Journal:  J Bone Miner Res       Date:  2019-10-24       Impact factor: 6.741

4.  3BP2-deficient mice are osteoporotic with impaired osteoblast and osteoclast functions.

Authors:  Noam Levaot; Paul D Simoncic; Ioannis D Dimitriou; Andrew Scotter; Jose La Rose; Adeline H M Ng; Thomas L Willett; Chiachien J Wang; Salima Janmohamed; Marc Grynpas; Ernst Reichenberger; Robert Rottapel
Journal:  J Clin Invest       Date:  2011-07-18       Impact factor: 14.808

5.  The adaptor 3BP2 is required for early and late events in FcεRI signaling in human mast cells.

Authors:  Erola Ainsua-Enrich; Damiana Alvarez-Errico; Alasdair M Gilfillan; César Picado; Joan Sayós; Juan Rivera; Margarita Martín
Journal:  J Immunol       Date:  2012-08-15       Impact factor: 5.422

6.  SH3BP2 is a critical regulator of macrophage and osteoclast response to M-CSF and RANKL stimulation.

Authors:  Mark S McMahon; Yasuyoshi Ueki
Journal:  HSS J       Date:  2008-10-25

Review 7.  Adapters in the organization of mast cell signaling.

Authors:  Damiana Alvarez-Errico; Eva Lessmann; Juan Rivera
Journal:  Immunol Rev       Date:  2009-11       Impact factor: 12.988

8.  Tyrosine phosphorylation of 3BP2 regulates B cell receptor-mediated activation of NFAT.

Authors:  Upasana Shukla; Tomoko Hatani; Kenji Nakashima; Kazuhiro Ogi; Kiyonao Sada
Journal:  J Biol Chem       Date:  2009-10-15       Impact factor: 5.157

9.  SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss.

Authors:  Tomoyuki Mukai; Shu Ishida; Remi Ishikawa; Teruhito Yoshitaka; Mizuho Kittaka; Richard Gallant; Yi-Ling Lin; Robert Rottapel; Marco Brotto; Ernst J Reichenberger; Yasuyoshi Ueki
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

10.  Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.

Authors:  Teruhito Yoshitaka; Shu Ishida; Tomoyuki Mukai; Mizuho Kittaka; Ernst J Reichenberger; Yasuyoshi Ueki
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.